Faye Drug Interactions

Effects of other medicaments on Cyproterone acetate + Ethinylestradiol (Faye): Interactions of other drugs (enzyme inducers, some antibiotics) with estrogen/progestogen combinations like Cyproterone acetate + Ethinylestradiol (Faye) may lead to breakthrough bleeding and/or contraceptive failure. Women on treatment with any of these drugs should be temporarily use a barrier method in addition to Cyproterone acetate + Ethinylestradiol (Faye) or choose another method of contraception. With microsomal enzyme-inducing drugs, the barrier method should be used during the time of concomitant drug administration and for 28 days after their discontinuation.
Women on treatment with antibiotics (except rifampicin and griseofulvin) should be use the barrier method until 7 days after discontinuation. If the period during which the barrier method is used runs beyond the end of the tablets in the Cyproteroneacetate + Ethinylestradiol (Faye) pack, the next pack should be started without the usual tablet-free interval.
Substances diminishing the efficacy of Cyproterone acetate + Ethinylestradiol (Faye) (enzyme-inducers and antibiotics): Enzyme induction (increase of hepatic metabolism): Interactions can occur with drugs that induce microsomal enzymes which can result in increased clearance of sex hormones (e.g. phenytoin, barbiturates, primidone, carbamazepine, rifampicin, and possibly also oxcarbazepine, topiramate, felbamate, griseofulvin and products containing St. John's wort).
Also HIV protease (e.g. ritonavir) and non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine), and combinations of them, have been reported to potentially increase hepatic metabolism.
Antibiotics (interference with enterohepatic circulation): Some clinical reports suggest that enterohepatic circulation of estrogens may decrease when certain antibiotic agents are given, which may reduce ethinylestradiol concentrations (e.g. penicillins, tetracyclines).
Effects of estrogen/progestogen combinations on other medicaments: Estrogen/progestogen combinations like Cyproterone acetate + Ethinylestradiol (Faye) may affect the metabolism of certain other drugs. Accordingly, plasma and tissue concentrations may either increase (e.g. cyclosporin) or decrease (e.g. lamotrigine).
Other forms of interactions: Laboratory tests: The use of preparations like Cyproterone acetate + Ethinylestradiol (Faye) may influence the results of certain laboratory tests, including biochemical parameters of liver, thyroid, adrenal and renal function, plasma levels of (carrier) proteins, e.g. corticosteroid binding globulin and lipid/lipoprotein fractions, parameters of carbohydrate metabolism and parameters of coagulation and fibrinolysis. Changes generally remain within the normal laboratory range.
Note: The prescribing information of concomitant medications should be consulted to identify potential interactions.